Cross-species studies of cognition relevant to drug discovery: a translational approach

British Journal of Pharmacology

Volumn 174, Issue 19, 2017, Pages 3191-3199

  Robbins, T W ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CENTENAFADINE; CITALOPRAM; DOPAMINE; FLUPENTIXOL; GUANFACINE; METHYLPHENIDATE; MODAFINIL; NORADRENALIN; NORSERTRALINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; UNCLASSIFIED DRUG; ADRENERGIC RECEPTOR AFFECTING AGENT; SEROTONIN UPTAKE INHIBITOR;

ATTENTION DEFICIT DISORDER; COGNITION; EXECUTIVE FUNCTION; EXPERIMENTAL ANIMAL; HUMAN; IMPULSIVENESS; MAJOR DEPRESSION; MENTAL DISEASE; NEUROIMAGING; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; ANIMAL; DEPRESSION; DRUG DEVELOPMENT; DRUG EFFECT; OBSESSIVE COMPULSIVE DISORDER; REACTION TIME; TRANSLATIONAL RESEARCH;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ATOMOXETINE HYDROCHLORIDE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COGNITION; DEPRESSION; DRUG DISCOVERY; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; REACTION TIME; SEROTONIN UPTAKE INHIBITORS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85019907002     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13826     Document Type: Review

References (58)

1. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The concise guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744–5869.
2. Alexander SPH, Peters JA, Kelly E, Marrion N, Benson HE, Faccenda E et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Ligand-gated ion channels. Br J Pharmacol 172: 5870–5903.
3. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al. (2015c). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110–6202.
4. Aron A, Poldrack RA (2006). Cortical and subcortical contributions to stop signal response inhibition: role of the subthalamic nucleus. J Neurosci 26: 2424–2433.
5. Bari A, Eagle DM, Mar AC, Robinson ESJ, Robbins TW (2009). Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats. Psychopharmacology (Berl) 205: 273–283.
6. Bari A, Mar AC, Theobald DEH, Elands SA, Oganya KC, Eagle DM et al. (2011). Prefrontal and monoaminergic contributions to top-signal performance in rats. J Neurosci 31: 9254–9263.
7. Bari A, Theobald DEH, Caprioli D, Mar AC, Aidoo-Micah A, Dalley JW et al. (2010). Serotonin modulates sensitivity to reward and negative feedback in a probabilistic reversal learning task in rats. Neuropsychopharmacology 35: 1290–1301.
8. Biederman J, Spencer T, Wilens T (2004). Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 7: 77–97.
9. Birrell JM, Brown VJ (2000). Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20: 4320–4324.
10. Borchert RJ, Rittman T, Passamonti L, Ye Z, Sami S, Jones SP et al. (2016). Atomoxetine enhances connectivity of prefrontal networks in Parkinson's disease. Neuropsychopharmacology 41: 2171–2177.
11. Brown VJ, Tait D (2016). Attentional set-shifting across species. Curr Top Behav Neurosci 28: 363–395.
12. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH et al. (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27: 699–711.
13. Chamberlain SR, Del Campo N, Dowson J, Müller U, Clark L, Robbins TW et al. (2007a). Atomoxetine improved response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 62: 977–984.
14. Chamberlain SR, Fineberg NA, Menzies LA, Blackwell AD, Bullmore ET, Robbins TW et al. (2007b). Impaired cognitive flexibility and motor inhibition in unaffected first-degree relatives of patients with obsessive-compulsive disorder. Am J Psychiatry 164: 335–338.
15. Chamberlain SR, Hampshire A, Müller U, Rubia K, Del Campo N, Craig K et al. (2009). Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry 65: 550–555.
16. Chamberlain SR, Menzies L, Hampshire A, Suckling J, Fineberg NA, del Campo N et al. (2008). Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science 321: 421–422.
17. Chamberlain SR, Müller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ (2006). Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 311: 861–863.
18. Clarke HF, Dalley JW, Crofts HS, Robbins TW, Roberts AC (2004). Cognitive inflexibility after prefrontal serotonin depletion. Science 304: 878–880.
19. Clemow DB, Bushe CJ (2015). Atomoxetine in patients with ADHD: a clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients. J Psychopharmacol 29: 1221–1230.
20. Corlett PR, Murray GK, Honey GD, Aitken MRF, Shanks DR, Robbins TW et al. (2007). Disrupted prediction-error in psychosis: evidence for an associative account of delusions. Brain 130: 2387–2400.
21. Crockett MJ, Clark L, Hauser MD, Robbins TW (2010). Serotonin selectively influences moral judgment and behavior through effects on harm aversion. Proc Natl Acad Sci U S A 107: 17433–17438.
22. Dalley JW, Robbins TW (2016). Fractionating impulsivity: neuropsychiatric implications. Nat Rev Neurosci 18: 158–171.
23. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW (2011). The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit hyperactivity disorder. Biol Psychiatry 69: e145–e157.
24. Dias R, Robbins TW, Roberts AC (1996). Dissociation in prefrontal cortex of affective and attentional shifts. Nature 380: 69–72.
25. Dreyer JK, Herrik KF, Berg RW, Hounsgaard JD (2010). Influence of phasic and tonic dopamine release on receptor activation. J Neurosci 30: 14273–14283.
26. Eagle DM, Baunez C, Hutcheson DM, Lehmann O, Shah AP, Robbins TW (2008). Stop signal reaction-time task performance: role of prefrontal cortex and subthalamic nucleus. Cereb Cortex 18: 178–188.
27. Eagle DM, Robbins TW (2003). Inhibitory control in rats performing on the stop signal reaction- time task: effects of lesions of the medial striatum and d-amphetamine. Behav Neurosci 117: 1302–1317.
28. Eagle DM, Tufft MR, Goodchild HL, Robbins TW (2007). Differential effects of modafinil and methylphenidate on stop-signal reaction time task performance in the rat, and interactions with the dopamine receptor antagonist cis-flupenthixol. Psychopharmacology 192: 193–206.
29. Eagle DM, Wong JC, Allan ME, Mar AC, Theobald DEH, Robbins TW (2011). Contrasting roles for dopamine D1 and D2 receptor subtypes in the dorsomedial striatum but not the nucleus accumbens core during behavioural inhibition in the stop signal task in rats. J Neurosci 31: 7349–7356.
30. Economidou D, Dalley JW, Everitt BJ (2011). Selective norepinephrine reuptake inhibition by atomoxetine prevents cue-induced heroin and cocaine seeking. Biol Psychiatry 69: 266–274.
31. Eisenegger C, Naef M, Linssen A, Clark L, Gandamaneni PK, Müller U et al. (2014). Role of dopamine D2 receptors in human reinforcement learning. Neuropsychopharmacology 39: 2366–2375.
32. Fernando AB, Economidou D, Theobald DEH, Zou MF, Newman AH, Spoelder M et al. (2012). Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists. Psychopharmacology 219: 341–352.
33. Friedman NP, Miyake A, Corley RP, Young SE, Defries JC, Hewitt JK (2006). Not all executive functions are related to intelligence. Psychol Sci 17: 72–179.
34. Gastambide F, Cotel MC, Gilmour G, O'Neill MJ, Robbins W, Tricklebank MD (2011). Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator. Neuropsychopharmacology 37: 1057–1066.
35. Goetghebeur P, Dias R (2009). Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat – a back translational study. Psychopharmacology 202: 287–293.
36. Humby T, Eddy JB, Good MA, Reichelt AC, Wlikinson LS (2013). A novel translational assay of response inhibition and impulsivity: effects of prefrontal cortex lesions, drugs used in ADHD and serotonin 2c receptor antagonists. Neuropsychopharmacology 38: 2150–2159.
37. Keeler JF, Robbins TW (2011). Translating cognition from animals to humans. Biochem Pharmacol 81: 1356–1366.
38. Kehagia AA, Housden CR, Regenthal R, Barker RA, Müller U, Rowe J et al. (2014). Targeting impulsivity in Parkinson's disease using atomoxetine. Brain 137: 1986–1997.
39. Leeson VC, Robbins TW, Matheson E, Hutton SB, Ron MA, Barnes TRE et al. (2009). Discrimination learning, reversal, and set-shifting in first-episode schizophrenia: stability over six years and specific associations with medication type and disorganization syndrome. Biol Psychiatry 66: 586–593.
40. Logan GD, Van Zandt T, Verbruggen F, Wagenmakers EJ (2014). On the ability to inhibit thought and action: general and special theories of an act of control. Psychol Rev 121: 66–95.
41. Müller U, Clark L, Lam ML, Moore RM, Murphy CL, Richmond NK et al. (2005). Lack of effects of guanfacine on executive and memory functions in healthy male volunteers. Psychopharmacology 182: 205–213.
42. Murphy FC, Michael A, Robbins TW, Sahakian BJ (2003). Neuropsychological impairment in patients with major depressive disorder: the effects of feedback on task performance. Psychol Med 33: 455–467.
43. Murphy FC, Smith KA, Cowen PJ, Robbins TW, Sahakian BJ (2002). The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers. Psychopharmacology 163: 42–53.
44. Murray GK, Corlett PR, Clark L, Pessiglione M, Blackwell AD, Honey G et al. (2008). Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Molecular Psychiat 13: 267–276.
45. Passimonti L, Luijten M, Ziauddeen H, Coyle-Gilchrist ITS, Rittman T, Brain SAE et al. (2017). Atomoxetine effects on attentional bias to drug-related cues in cocaine dependent Individuals. Psychopharmacology in press.
46. Pessiglione M, Seymour B, Flandin G, Dolan RJ, Frith CD (2006). Dopamine dependent prediction errors underpin reward-seeking behaviour in humans. Nature 442: 1042–1045.
47. Robinson ESJ, Eagle DM, Mar AC, Bari A, Banerjee G, Jiang X et al. (2008). Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat. Neuropsychopharmacology 33: 1028–1037.
48. Rygula R, Clarke HF, Cardinal RN, Cockcroft GJ, Xia J, Dalley JW et al. (2014). Role of central serotonin in anticipation of rewarding and punishing outcomes: effects of selective amygdala or orbitofrontal 5-HT depletion. Cereb Cortex 25: 3064–3076.
49. Schultz W (2015). Neuronal reward and decision signals: from theories to data. Physiol Rev 95: 853–951.
50. Seeman P (2010). Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 4: 56–73.
51. Solanto MV, Abikoff H, Sonuga-Barke E, Schachar R, Logan GD, Wigal T et al. (2001). The ecological validity of delay aversion and response inhibition as measures of impulsivity in AD/HD: a supplement to the NIMH multimodal treatment study of AD/HD. J Abnorm Child Psychol 29: 215–228.
52. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 44: D1054–D1068.
53. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ (2004a). Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry 55: 1031–1040.
54. Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ (2004b). Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29: 1363–1373.
55. Van der Kooij MA, Glennon JC (2007). Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder Neurosci. Biobehav Rev 31: 597–618.
56. Whelan R, Conrod PJ, Poline JB, Lourdusamy A, Banaschewski T, Barker GJ et al., the IMAGEN Consortium (2012). Adolescent impulsivity phenotypes characterized by distinct brain networks. Nature Neurosci 15: 920–925.
57. Yan TC, Dudley JA, Weir RK, Grabowska EA, Pena-Oliver Y, Ripley TL et al. (2011). Performance deficits of NK1 receptor knockout mice in the 5-choice serial reaction-time task: effects of d-Amphetamine, stress and time of day. PLoS One 6: e17586.
58. Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T et al. (2015). Improving response inhibition in Parkinson's disease with atomoxetine. Biol Psychiatry 77: 740–748.